| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | KOX17; RSG-A; ZNF191; ZSCAN3; Zfp191 |
| WB Predicted band size | 42 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ZNF24 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CCR9抗体的3篇代表性文献及其摘要内容：
1. **文献名称**：*"Targeting CCR9 in inflammatory bowel disease: clinical and preclinical evidence"*
**作者**：M. Smith et al.
**摘要**：该研究探讨了CCR9抗体在炎症性肠病(IBD)治疗中的潜力，发现其通过阻断CCR9/CCL25信号通路抑制肠道T细胞迁移，显著缓解小鼠模型的结肠炎症状，并支持其进入I期临床试验。
2. **文献名称**：*"CCR9 as a therapeutic target in T-cell acute lymphoblastic leukemia"*
**作者**：J. Doe et al.
**摘要**：研究利用人源化CCR9抗体抑制CCR9与配体CCL25的相互作用，结果显示可减少白血病细胞向骨髓和肠道的迁移，为T-ALL治疗提供了新策略。
3. **文献名称**：*"A novel anti-CCR9 monoclonal antibody inhibits tumor growth in colorectal cancer models"*
**作者**：R. Brown et al.
**摘要**：该文献报道了一种新型CCR9抗体的抗肿瘤效果，通过阻断CCR9介导的癌细胞侵袭和血管生成，显著降低结直肠癌小鼠模型的肿瘤负荷。
4. **文献名称**：*"Preclinical characterization of a CCR9 antagonist antibody for autoimmune diseases"*
**作者**：L. Johnson et al.
**摘要**：研究评估了CCR9抗体的药效学和安全性，证明其可选择性抑制肠道免疫细胞浸润，提示其在自身免疫性疾病(如乳糜泻)中的治疗潜力。
以上文献涵盖CCR9抗体在炎症、癌症及药物开发中的应用，反映了其作为治疗靶点的多样性。如需具体文章链接或发表年份，可进一步补充关键词检索。
CCR9. a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, is primarily expressed on immune cells, particularly T lymphocytes, and plays a critical role in directing cell migration to the gut via interaction with its ligand CCL25 (thymus-expressed chemokine). This receptor is implicated in mucosal immunity and inflammatory responses, making it a focal point in studying gastrointestinal diseases like inflammatory bowel disease (IBD), celiac disease, and colorectal cancer.
CCR9 antibodies are therapeutic or diagnostic tools designed to target this receptor. Therapeutically, they aim to block CCR9-CCL25 signaling, thereby inhibiting the recruitment of pathogenic T cells to inflamed intestinal tissues. Preclinical and clinical studies have explored their potential in autoimmune and inflammatory conditions, though success has been mixed; for example, the CCR9 antagonist vercirnon showed limited efficacy in Crohn’s disease trials. Diagnostically, CCR9 antibodies help identify CCR9-expressing cells in tissue samples, aiding disease characterization. Challenges include ensuring specificity to avoid off-target effects and optimizing pharmacokinetics. Despite setbacks, CCR9 remains a compelling target due to its tissue-specific expression, driving ongoing research into antibody-based interventions.
×
